| Report | Options implied | Actual move | Market was |
|---|---|---|---|
| 05/06/2026 | ±2.3% | -1.2% | over-priced |
| 02/04/2026 | ±2.5% | +4.4% | under-priced |
| 11/14/2025 | ±2.0% | -1.2% | over-priced |
| 08/06/2025 | ±2.9% | -0.2% | over-priced |
| 05/07/2025 | ±2.8% | +1.1% | over-priced |
| 02/05/2025 | ±2.0% | +11.3% | under-priced |
| 11/19/2024 | ±1.6% | -0.1% | over-priced |
| 07/31/2024 | ±2.2% | +3.6% | under-priced |
| Quarter | EPS (dil.) | Revenue | Net income |
|---|---|---|---|
| Q2 FY2026 | $1.00 | $6.1B | $613M |
| Q1 FY2026 | $0.85 | $5.8B | $524M |
| Q4 FY2025 | — | $6.4B | $1.7B |
| Q3 FY2025 | $1.07 | $6.1B | $701M |
JCI (JCI) reports in 6 days, with the next report estimated for 11/02/2026. Across the last 8 reports, options priced an average ±2.3% earnings move while the stock actually moved 2.9% on average — the market has been roughly fair on JCI's earnings risk. Fundamentals into the print: EPS up 38.9% year-over-year, revenue up 8.2%. QuantLogix's live 5-factor engine currently reads JCI as a buy at 74/100.
Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →